Skip to content
2000
Volume 18, Issue 4
  • ISSN: 1874-4710
  • E-ISSN: 1874-4729

Abstract

Introduction

The ideal [131I]Sodium Iodide activity for intermediate-risk thyroid cancer treatment is still uncertain. The objective of this study is to compare the biochemical responses to radioiodine therapy (RIT) of intermediate-risk thyroid cancer patients administered [131I]Sodium Iodide at doses of 3700 MBq (100 mCi) and 5550 MBq (150 mCi).

Methods

A retrospective study was conducted by reviewing the medical records of intermediate-risk thyroid cancer patients who received RIT between 2016 and 2020 at a reference cancer hospital in Brazil. Sociodemographic and clinical data were evaluated at the time of diagnosis. Clinical data during two years of follow-up were reviewed, and biochemical responses were determined according to the American Thyroid Association (ATA, 2015 version). Responses to doses of 3700 MBq (100 mCi) and 5550 MBq (150 mCi) of [131I]Sodium Iodide were compared.

Results

No significant statistical differences were observed concerning the biochemical therapeutic responses of patients treated with 3700 MBq or 5550 MBq ( = 0.088). The presence of nodal metastasis and positive pre-RIT thyroglobulin did not influence biochemical responses to radioiodine.

Discussion

According to ATA 2015 guidelines, RIT may be administered to patients classified at intermediate risk for the ablation of post-surgical tissue remnants, as well as an adjuvant treatment for potential persistent tumor foci and to reduce recurrence risks. These recommendations, however, do not specify the appropriate radioiodine dosage and this has been a topic of extensive debate.

Conclusion

Intermediate risk thyroid-cancer patients presented similar therapeutic responses to the doses of 3700 MBq and 5550 MBq [131I]Sodium Iodide.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crp/10.2174/0118744710374569250415095218
2025-12-01
2025-09-27

  • From This Site

    /content/journals/crp/10.2174/0118744710374569250415095218
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LorussoL. CappagliV. ValerioL. GianiC. ViolaD. PuleoL. GambaleC. MinaldiE. CampopianoM.C. MatroneA. BotticiV. AgateL. MolinaroE. EliseiR. Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities.Int. J. Mol. Sci.2021226311710.3390/ijms22063117 33803747
     [Google Scholar]
  2. SantosM.O. LimaF.C.S. MartinsL.F.L. OliveiraJ.F.P. AlmeidaL.M. CancelaM.C. Estimated Cancer Incidence in Brazil, 2023-2025.Rev. Bras. Cancerol.202369110.32635/2176‑9745.RBC.2023v69n1.3700
     [Google Scholar]
  3. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  4. AminM.B. GreeneF.L. EdgeS.B. ComptonC.C. GershenwaldJ.E. BrooklandR.K. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. In: CA Cancer J. Clin; 2017672939910.3322/caac.21388 28094848
     [Google Scholar]
  5. HaugenB.R. AlexanderE.K. BibleK.C. DohertyG.M. MandelS.J. NikiforovY.E. PaciniF. RandolphG.W. SawkaA.M. SchlumbergerM. SchuffK.G. ShermanS.I. SosaJ.A. StewardD.L. TuttleR.M. WartofskyL. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer.Thyroid2016261113310.1089/thy.2015.0020 26462967
     [Google Scholar]
  6. RaueF. Frank-RaueK. Thyroid cancer: Risk-stratified management and individualized therapy.Clin. Cancer Res.201622205012502110.1158/1078‑0432.CCR‑16‑0484 27742787
     [Google Scholar]
  7. SchlumbergerM. LeboulleuxS. Current practice in patients with differentiated thyroid cancer.Nat. Rev. Endocrinol.202117317618810.1038/s41574‑020‑00448‑z 33339988
     [Google Scholar]
  8. DehbiH.M. MallickU. WadsleyJ. NewboldK. HarmerC. HackshawA. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): Long-term results of an open-label, non-inferiority randomised controlled trial.Lancet Diabetes Endocrinol.201971445110.1016/S2213‑8587(18)30306‑1 30501974
     [Google Scholar]
  9. MakazlievaT. VaskovaO. StojanoskiS. NevenaM. MiladinovaD. StefanovskaV.V. Prognostic factors in thyroid carcinomas: A 17-year outcome study.Arch. Endocrinol. Metab.2019641303710.20945/2359‑3997000000175 31576963
     [Google Scholar]
  10. BaudinC. Lussey-LepoutreC. BressandA. BuffetC. MenegauxF. SoretM. BroggioD. BassinetC. HuetC. ArmengolG. LeenhardtL. BernierM.O. Salivary dysfunctions and consequences after radioiodine treatment for thyroid cancer: Protocol for a self-controlled study (start study).JMIR Res. Protoc.2022117e3556510.2196/35565 35867385
     [Google Scholar]
  11. HongC.M. ShinJ.Y. KimB.I. SongH.C. YoonJ.K. WonK.S. KimS.M. ChoI.H. JeongS.Y. LeeS.W. LeeJ. Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: A multicenter retrospective study.Eur. J. Nucl. Med. Mol. Imaging20224951661167010.1007/s00259‑021‑05608‑5 34773164
     [Google Scholar]
  12. BarbosaM.P. MomessoD. BulzicoD.A. FariasT. DiasF. LimaR.A. CorboR. VaismanM. VaismanF. Metastatic lymph node characteristics as predictors of recurrence/persistence in the neck and distant metastases in differentiated thyroid cancer.Arch. Endocrinol. Metab.201761658458910.1590/2359‑3997000000307 29412383
     [Google Scholar]
  13. SparanoC. MoogS. HadouxJ. DupuyC. Al GhuzlanA. BreuskinI. GuerlainJ. HartlD. BaudinE. LamartinaL. Strategies for radioiodine treatment: What’s new.Cancers 20221415380010.3390/cancers14153800 35954463
     [Google Scholar]
  14. HaugenB.R. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: What is new and what has changed?Cancer2017123337238110.1002/cncr.30360 27741354
     [Google Scholar]
  15. AnsariM. Rezaei TaviraniM. Assessment of different radioiodine doses for post-ablation therapy of thyroid remnants: A systematic review.Iran. J. Pharm. Res.2022211e12382510.5812/ijpr‑123825 36060901
     [Google Scholar]
  16. JeongJ.H. KongE.J. JeongS.Y. LeeS.W. ChoI.H. Ah ChunK. LeeJ. AhnB.C. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.Nucl. Med. Commun.201738322823310.1097/MNM.0000000000000636 27984538
     [Google Scholar]
  17. Gómez-PérezA.M. García-AlemánJ. Molina-VegaM. Sebastián OchoaA. Pérez GarcíaP. Mancha DoblasI. TinahonesF.J. Efficacy of low-dose radioiodine ablation in low-and intermediate-risk differentiated thyroid cancer: A retrospective comparative analysis.J. Clin. Med.20209258110.3390/jcm9020581 32098039
     [Google Scholar]
  18. AhnJ. SongE. KimW.G. KimT.Y. KimW.B. ShongY.K. JeonM.J. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response.Endocrine202067362362910.1007/s12020‑019‑02142‑1 31776976
     [Google Scholar]
  19. OraM. NazarA.H. MishraP. BaraiS. AryaA. PradhanP.K. GambhirS. Factors predicting the risk of biochemical incomplete response in well-differentiated thyroid cancer after total thyroidectomy.Nucl. Med. Commun.202142111187119410.1097/MNM.0000000000001448 34132236
     [Google Scholar]
  20. ParvathareddyS.K. SirajA.K. AhmedS.O. AnnaiyappanaiduP. Al-RasheedM. Al-HaqawiW. QadriZ. Al-SobhiS.S. Al-DayelF. Al-KurayaK.S. Predicting factors and clinical outcome of biochemical incomplete response in middle eastern differentiated thyroid carcinoma.Endocrine202486126827510.1007/s12020‑024‑03844‑x 38696058
     [Google Scholar]
  21. JamesD.L. RyanÉ.J. DaveyM.G. QuinnA.J. HeathD.P. GarryS.J. BolandM.R. YoungO. LoweryA.J. KerinM.J. Radioiodine remnant ablation for differentiated thyroid cancer.JAMA Otolaryngol. Head Neck Surg.2021147654455210.1001/jamaoto.2021.0288 33792650
     [Google Scholar]
  22. TuttleR.M. AhujaS. AvramA.M. BernetV.J. BourguetP. DanielsG.H. DillehayG. DraganescuC. FluxG. FührerD. GiovanellaL. GreenspanB. LusterM. MuylleK. SmitJ.W.A. Van NostrandD. VerburgF.A. HegedüsL. Controversies, consensus, and collaboration in the use of 131I therapy in differentiated thyroid cancer: A joint statement from the American thyroid association, the European association of nuclear medicine, the society of nuclear medicine and molecular imaging, and the European thyroid association.Thyroid201929446147010.1089/thy.2018.0597 30900516
     [Google Scholar]
  23. KazaureH.S. RomanS.A. SosaJ.A. Aggressive variants of papillary thyroid cancer: Incidence, characteristics and predictors of survival among 43,738 patients.Ann. Surg. Oncol.20121961874188010.1245/s10434‑011‑2129‑x 22065195
     [Google Scholar]
  24. SússS.K.A. MesaC.O. CarvalhoG.A. MiasakiF.Y. ChavesC.P. FuserD.C. CorboR. MomessoD. BulzicoD.A. GrafH. VaismanF. Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.Arch. Endocrinol. Metab.201862214915610.20945/2359‑3997000000025 29641738
     [Google Scholar]
/content/journals/crp/10.2174/0118744710374569250415095218
Loading
Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [131I]Sodium Iodide
Current Radiopharmaceuticals 18, 293 (2025); https://doi.org/10.2174/0118744710374569250415095218
/content/journals/crp/10.2174/0118744710374569250415095218
/content/journals/crp/10.2174/0118744710374569250415095218
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): biochemical response; comparison; dose-response; intermediate risk [131I]sodium iodide; Radioiodine therapy; thyroid cancer

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test